These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

322 related items for PubMed ID: 19553801

  • 1. Combination therapy for age-related macular degeneration.
    Patel S.
    Retina; 2009 Jun; 29(6 Suppl):S45-8. PubMed ID: 19553801
    [Abstract] [Full Text] [Related]

  • 2. Strategies for inhibiting vascular endothelial growth factor.
    Kaiser PK.
    Retina; 2009 Jun; 29(6 Suppl):S15-7. PubMed ID: 19553789
    [Abstract] [Full Text] [Related]

  • 3. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
    Ferrara N, Damico L, Shams N, Lowman H, Kim R.
    Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284
    [Abstract] [Full Text] [Related]

  • 4. Re: development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
    Ziemssen F, Heiduschka P, Schraermeyer U, Tübingen Bevacizumab Study Group.
    Retina; 2007 Oct; 27(8):1154-6; author reply 1156-8. PubMed ID: 18040264
    [No Abstract] [Full Text] [Related]

  • 5. Age-related macular degeneration.
    Brucker AJ.
    Retina; 2009 Jun; 29(6 Suppl):S2-4. PubMed ID: 19553791
    [Abstract] [Full Text] [Related]

  • 6. Rationale for combination therapy in age-related macular degeneration.
    Spaide RF.
    Retina; 2009 Jun; 29(6 Suppl):S5-7. PubMed ID: 19553803
    [Abstract] [Full Text] [Related]

  • 7. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M, Karl D, Georgopoulos M, Benesch T, Sacu S, Polak K, Zlabinger GJ, Schmidt-Erfurth U.
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [Abstract] [Full Text] [Related]

  • 8. Combination therapy using the small interfering RNA bevasiranib.
    Singerman L.
    Retina; 2009 Jun; 29(6 Suppl):S49-50. PubMed ID: 19553802
    [Abstract] [Full Text] [Related]

  • 9. Opportunities and challenges in the development of combination therapy for the treatment of retinal diseases.
    Hohman TC.
    Retina; 2009 Jun; 29(6 Suppl):S51-3. PubMed ID: 19553804
    [Abstract] [Full Text] [Related]

  • 10. Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration.
    Tuñón J, Ruiz-Moreno JM, Martín-Ventura JL, Blanco-Colio LM, Lorenzo O, Egido J.
    Surv Ophthalmol; 2009 Jun; 54(3):339-48. PubMed ID: 19422962
    [Abstract] [Full Text] [Related]

  • 11. Joint Antiangiogenic Effect of ATN-161 and Anti-VEGF Antibody in a Rat Model of Early Wet Age-Related Macular Degeneration.
    Wang WQ, Wang FH, Qin WX, Liu HY, Lu B, Chung C, Zhu J, Gu Q, Shi W, Wen C, Wu F, Zhang K, Sun XD.
    Mol Pharm; 2016 Sep 06; 13(9):2881-90. PubMed ID: 27089240
    [Abstract] [Full Text] [Related]

  • 12. Anti-angiogenic therapy of exudative age-related macular degeneration: current progress and emerging concepts.
    Noël A, Jost M, Lambert V, Lecomte J, Rakic JM.
    Trends Mol Med; 2007 Aug 06; 13(8):345-52. PubMed ID: 17644433
    [Abstract] [Full Text] [Related]

  • 13. Photoreceptor status after antivascular endothelial growth factor therapy in exudative age-related macular degeneration.
    Sayanagi K, Sharma S, Kaiser PK.
    Br J Ophthalmol; 2009 May 06; 93(5):622-6. PubMed ID: 19208677
    [Abstract] [Full Text] [Related]

  • 14. Review of combination therapies for neovascular age-related macular degeneration.
    Couch SM, Bakri SJ.
    Semin Ophthalmol; 2011 May 06; 26(3):114-20. PubMed ID: 21609223
    [Abstract] [Full Text] [Related]

  • 15. Anti-VEGF agents for age-related macular degeneration.
    Ozkiris A.
    Expert Opin Ther Pat; 2010 Jan 06; 20(1):103-18. PubMed ID: 20021287
    [Abstract] [Full Text] [Related]

  • 16. Anti-Vascular Endothelial Growth Factor Injection for Exudative Age-related Macular Degeneration in Patients with Vitreo-Macular Traction.
    Querques G.
    Am J Ophthalmol; 2009 Feb 06; 147(2):375-6; author reply 376-7. PubMed ID: 19166716
    [No Abstract] [Full Text] [Related]

  • 17. Approaches toward combining photodynamic therapy with pharmaceuticals that alter vascular microenvironment.
    Busch T.
    Retina; 2009 Jun 06; 29(6 Suppl):S36-8. PubMed ID: 19553798
    [Abstract] [Full Text] [Related]

  • 18. Photodynamic therapy in the anti-VEGF era.
    Fine HF.
    Br J Ophthalmol; 2007 Jun 06; 91(6):707-8. PubMed ID: 17510474
    [Abstract] [Full Text] [Related]

  • 19. A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Arias L, Ruiz-Moreno JM, Gómez-Ulla F, Fernández M, Montero J.
    Retina; 2009 Jun 06; 29(10):1444-9. PubMed ID: 19730163
    [Abstract] [Full Text] [Related]

  • 20. Pathology beyond neovascularization: new targets in age-related macular degeneration.
    Heier JS.
    Retina; 2009 Jun 06; 29(6 Suppl):S39-41. PubMed ID: 19553799
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.